Iovance Biotherapeutics, Inc.
NASDAQ:IOVABiotechnology
-$0.04 today
- Market cap
- $3.46B
- Beta
- 0.70
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.85
Volume 6.99M
Average 14.09M
IOVA Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Iovance Biotherapeutics, Inc.NASDAQ: IOVA
Financing Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Financing cash flow dips below year-ago levels
Q3 FY2026 financing cash flow of $86.28M fell 2.0% year over year, behind the +15.9% change in trailing-twelve-month financing cash flow. Sequentially, it rose 75.1% from the prior quarter. Over 3 fiscal years it compounded at +16.5% a year.
Context
- Financing cash flow amounted to 114.1% of revenue in FY2025, down 124.0 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -2.0% toward the trailing-twelve-month pace of +15.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 300.77M USD
- Year-over-year change
- -23.0%
- 4-year CAGR
- +5.9%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 300.77M | -23.0% |
| FY2024 | 2024-12-31 | 390.66M | -15.6% |
| FY2023 | 2023-12-31 | 462.96M | +143.5% |
| FY2022 | 2022-12-31 | 190.15M | -20.5% |
| FY2021 | 2021-12-31 | 239.27M | — |
Financing Cash Flow vs competitors
How IOVA compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +15.9% is the 8th highest of 10, against a peer median of +121.3%.
- Financing cash flow amounts to 75.5% of revenue for IOVA, versus a peer median of 86.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $4.96B USD | — | — | 120.1% | |
| LTM Sep 2026 | $436.09M USD | +91.6% | +2614.9% | — | |
| LTM Sep 2026 | $376.3M USD | -16.8% | +19.7% | 206.1% | |
| LTM Sep 2026 | $286.08M USD | +15.9% | +16.5% | 75.5% | |
| LTM Mar 2026 | $139.89M USD | +403.3% | -66.8% | — | |
| LTM Sep 2026 | $115.15M USD | +822385.3% | — | 8.5% | |
| LTM Jun 2026 | €112.12M EUR | +142.6% | -67.0% | 4.2% | |
| LTM Mar 2026 | $70.43M USD | +7606.1% | +538.8% | 7043.4% | |
| LTM Dec 2025 | $10.49M USD | -95.8% | +236.9% | — | |
| LTM Mar 2026 | $10.47M USD | +121.3% | -60.2% | 2.7% | |
| LTM Mar 2026 | $5.49M USD | +24.7% | -15.8% | 86.9% | |
| Peer median (excluding IOVA) | — | +121.3% | +1.9% | 86.9% | |
Competitors are the stored peer set for IOVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (342.25M) | (395.89M) | (444.04M) | (372.18M) | (390.98M) |
| Depreciation & Amortization | 13.98M | 21.14M | 33.13M | 43.61M | 47.32M |
| Deferred Income Tax | 0 | 0 | (3.48M) | (2.83M) | (2.07M) |
| Stock-Based Compensation | 69.77M | 84.02M | 62.63M | 109.63M | 61.58M |
| Change in Working Capital | 24.55M | (2.89M) | (6.52M) | (122.56M) | (24.27M) |
| Accounts Receivables | 0 | 0 | (149K) | (69.19M) | (13.11M) |
| Inventory | 0 | 0 | (10.12M) | (39.92M) | (14.21M) |
| Accounts Payables | 6.98M | 5.88M | 4.83M | (7.84M) | (6.66M) |
| Other Working Capital | 17.58M | (8.78M) | (1.08M) | (5.61M) | 9.71M |
| Other Non-Cash Items | 6.01M | 871K | (3.54M) | (8.65M) | 6.01M |
| Operating Cash Flow | (227.94M) | (292.76M) | (361.82M) | (352.98M) | (302.41M) |
| Capital Expenditures | (37.57M) | (20.43M) | (22.29M) | (11.07M) | (33.84M) |
| Acquisitions (Net) | (37.71M) | (276.88M) | (212.63M) | (52.57M) | 0 |
| Purchases of Investments | (725.21M) | (245.82M) | (205.9M) | (460.77M) | (318.67M) |
| Sales of Investments | 762.91M | 522.7M | 285.58M | 428M | 400M |
| Other Investing Activities | 37.71M | 276.88M | 0 | 0 | 0 |
| Investing Cash Flow | 132K | 256.46M | (155.24M) | (96.41M) | 47.5M |
| Debt Repayment | 1M | 0 | 0 | 0 | 0 |
| Common Stock Issued | 203.16M | 189.5M | 463.28M | 397.3M | 306.31M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 35.11M | 648K | (322K) | (6.64M) | (7.06M) |
| Financing Cash Flow | 239.27M | 190.15M | 462.96M | 390.66M | 300.77M |
| Effect of Forex Changes | 0 | 0 | (2.74M) | (541K) | 1.52M |
| Net Change in Cash | 11.46M | 153.85M | (56.84M) | (59.27M) | 47.38M |
| Free Cash Flow | (265.52M) | (313.18M) | (384.11M) | (364.05M) | (336.24M) |
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
Intrinsic Alpha fair value
Locked
Current Price
$7.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.